News

Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention

February 12, 2015

Highlights:
  • This review provides an up-to-date survey of the drug design effort placed on the compstatin family of C3 inhibitors, highlighting the most promising drug candidates.
  • It discusses translational challenges in complement drug discovery and peptide drug development.
  • It reviews concerns related to systemic C3 interception.
Author and source information

Authors: Mastellos DC, Yancopoulou D, Kokkinos P, Huber-Lang M, Hajishengallis G, Biglarnia AR, Lupu F, Nilsson B, Risitano AM, Ricklin D, Lambris JD.
Reference: Eur J Clin Invest. 2015 Apr;45(4):423-40. doi: 10.1111/eci.12419. Epub 2015 Mar 9.
Source: www.ncbi.nlm.nih.gov

 

 

Comments are closed.